OnKure Therapeutics (NASDAQ:OKUR - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for OnKure Therapeutics in a report issued on Thursday, October 17th. HC Wainwright analyst R. Burns forecasts that the company will earn ($1.12) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for OnKure Therapeutics' current full-year earnings is ($1.62) per share. HC Wainwright also issued estimates for OnKure Therapeutics' Q2 2025 earnings at ($1.16) EPS, Q3 2025 earnings at ($1.19) EPS and Q4 2025 earnings at ($1.21) EPS.
Other analysts have also issued reports about the company. Oppenheimer began coverage on OnKure Therapeutics in a research note on Thursday, October 10th. They set an "outperform" rating and a $35.00 price target on the stock. Lifesci Capital upgraded shares of OnKure Therapeutics to a "strong-buy" rating in a research report on Thursday, October 10th.
Read Our Latest Report on OnKure Therapeutics
OnKure Therapeutics Stock Up 3.1 %
OKUR stock traded up $0.56 during midday trading on Friday, reaching $18.51. 68,878 shares of the stock were exchanged, compared to its average volume of 27,711. OnKure Therapeutics has a 52 week low of $9.80 and a 52 week high of $86.70. The firm has a market capitalization of $61.82 million, a P/E ratio of -1.10 and a beta of 0.21.
OnKure Therapeutics Company Profile
(
Get Free Report)
Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.
Featured Stories
Before you consider OnKure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OnKure Therapeutics wasn't on the list.
While OnKure Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
